EP Patent

EP0563062B1 — Hexapeptides deriving from aglucoteicoplanin and a process for preparing them

Assigned to Vicuron Pharmaceuticals LLC · Expires 1996-01-10 · 30y expired

What this patent protects

Hexapeptides of formula (I) deriving from aglucoteicoplanin and their salts with acids and bases as well as their inner salts, wherein R is hydrogen or a protecting group of the amino moiety. The products of formula (I), wherein R is hydrogen, possess antimicrobial activity in pa…

USPTO Abstract

Hexapeptides of formula (I) deriving from aglucoteicoplanin and their salts with acids and bases as well as their inner salts, wherein R is hydrogen or a protecting group of the amino moiety. The products of formula (I), wherein R is hydrogen, possess antimicrobial activity in particular against coagulase-negative strains and some S. aureus and S. epidermidis strains which have low sensitivity toward teicoplanin. The hexapeptides are produced by reductive cleavage of aglucoteicoplanin with alkali metal borohydrides in the presence of a hydroalcoholic mixture as solvent.

Drugs covered by this patent

Patent Metadata

Patent number
EP0563062B1
Jurisdiction
EP
Classification
—
Expires
1996-01-10
Drug substance claim
No
Drug product claim
No
Assignee
Vicuron Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.